Choosing Your First Market in Health Tech

Most early health tech companies can name six plausible customers. That is the problem. A plausible market is not a first market, and pursuing several at once produces a pipeline where nothing is far enough along to learn from.

Score candidate segments on four axes

The first market is the one where the shortest path to a signature exists, not the largest one.

• Evidence fit: where does your existing clinical or economic data already answer the buyer question, without new studies?
• Cycle length: who can buy inside one budget cycle, and who needs capital approval you cannot influence?
• Pain intensity: is the current workflow merely imperfect, or is it actively costing the buyer money, staff, or compliance exposure?
• Reference value: will a win here open the next ten accounts, or is it an outlier nobody else looks to?

Position against the workflow, not the competitor

In most health tech categories the real alternative is not a rival product; it is what the department does today. Comparison charts against a competitor answer a question the buyer has not asked yet. The question they have asked is whether changing anything is worth the disruption.

Price for the review, not the pitch

A price that lands well in a demo and fails at finance review is not a price. Build the model in the terms the reviewer uses: cost per procedure, staff hours returned, readmissions or complications avoided, existing line item displaced. If you cannot express your value that way, the segment probably is not the beachhead.

The outcome argument

Beachhead choice is also a clinical choice. It determines which patients see a technology first and how quickly the evidence base grows. The strongest first markets are usually the ones where the commercial case and the patient case point the same direction, because those are the deals that survive committee scrutiny.